{"organizations": [], "uuid": "7265a88e0348164624f7b6545879440266f675b2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-resverlogix-medison-pharma-ltd-ann/brief-resverlogix-medison-pharma-ltd-announce-strategic-licensing-agreement-idUSFWN1P30QV", "country": "US", "domain_rank": 408, "title": "BRIEF-Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T22:13:00.000+02:00", "replies_count": 0, "uuid": "7265a88e0348164624f7b6545879440266f675b2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-resverlogix-medison-pharma-ltd-ann/brief-resverlogix-medison-pharma-ltd-announce-strategic-licensing-agreement-idUSFWN1P30QV", "ord_in_thread": 0, "title": "BRIEF-Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement", "locations": [], "entities": {"persons": [], "locations": [{"name": "israel", "sentiment": "none"}], "organizations": [{"name": "medison pharma ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "resverlogix corp", "sentiment": "negative"}, {"name": "medison", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Resverlogix Corp:\n* RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT\n* RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​\n* RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION\n* RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO‘S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY\n* RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T22:13:00.000+02:00", "crawled": "2018-01-09T17:09:25.009+02:00", "highlightTitle": ""}